ABO-Incompatible kidney transplantation

著者

書誌事項

ABO-Incompatible kidney transplantation

Kota Takahashi

Elsevier, c2001

大学図書館所蔵 件 / 全5件

この図書・雑誌をさがす

注記

Includes bibliographical references and index

内容説明・目次

内容説明

ABO incompatible kidney transplantation is indicated for patients for whom no ABO-identical or minor mismatch donor is available. Since the author and his colleagues performed the first ABO-incompatible kidney transplantation in Japan in 1989, 400 such transplantations have been performed in 41 hospitals in Japan and this practice has contributed to a number of developments. One is a clearer and more suitable model for conceptualizing the mechanism of humoural immune response which enables identification of antigens and antibodies and a therapeutic strategy against rejection. In this text, the rejection mechanisms are discussed not only from the perspective of immunology but also viewed from different angles, including anatomy, microscopic and macroscopic pathology, molecular biology and haematology. Immunosuppressive therapy is discussed, divided in four categories: extracorporeal immunomodulation with removal of humoural antibodies; drug therapy to suppress cellular immunity; splenectomy; and anticoagulation therapy. Surgical procedures for kidney transplantation and splenectomy are treated, including discussion of the best timing for the latter. The book gives an overview, complete with statistics, the results of questionnaires, and discussions of 17 case histories.

目次

Preface. Personal History. Chapter 1. History. Chapter 2. Current status of treatment for chronic renal failure and factors behind increasing use of ABO-incompatible kidney transplantation in Japan. Chapter 3. Indications and considerations. 3.1. Indications. 3.2. Crossmatch test. 3.3. Anti-A/anti-B (anti-A, anti-B, and anti-AB) antibodies. 3.4. Age and dialysis history. 3.4.1. Recipient. 3.4.2. Donor. 3.5. Anticoagulation therapy. 3.6. Informed consent. Chapter 4. Blood group antigens and their antibodies. 4.1. ABO blood group antigens. 4.2. Measuring anti-A and anti-B antibodies. 4.3. Origin of ABO blood group glycosyltransferase. 4.4. ABO blood group antigens and other blood group antigens. Chapter 5. Rejection. 5.1. Considerations regarding rejection mechanism. 5.2. Mechanism of rejection in ABO-incompatible kidney transplantation. Chapter 6. Immunosuppressive therapy. 6.1. Considerations for immunosuppressive therapy in kidney transplantation. 6.2. Induction period immunosuppressive therapy in ABO-incompatible kidney transplantation. 6.2.1. Pretransplant extracorporeal immunomodulation. 6.2.1.1. Actual status of extracorporeal immunomodulation and blood purification techniques. 6.2.1.1.1. Simple plasma exchange. 6.2.1.1.2. Fractional plasma exchange. 6.2.1.1.3. Blood adsorption and immunoadsorption. 6.2.2. Pharmacotherapy for immunosuppression. 6.2.2.1. Evolution of induction period immunosuppressive therapy in ABO-incompatible kidney transplantation. 6.2.2.1.1. Stage 1: January 1989 through March 1996. 6.2.2.1.2. Stage 2: April 1996 through February 1999. 6.2.2.1.3. Stage 3: March 1999 through December 1999. 6.2.2.1.4. Stage 4: January 2000 to present. 6.2.2.2. Immunosuppressive agents for induction period. 6.2.2.2.1. Calcineurin inhibitors. 6.2.2.2.2. Steroid. 6.2.2.2.3. Cyclophosphamide. 6.2.2.2.4. Antilymphocyte globulin. 6.3. Immunosuppr

「Nielsen BookData」 より

詳細情報

ページトップへ